Precision Medicines Against
LIpid-MEdiated Targets
At Lime, we are inventing breakthrough lipid-targeting therapeutics using our novel drug discovery platform.
Lime Therapeutics is a fast-growing biotechnology company focused on making a difference for patients. We are a spinout company developing new technology invented at Memorial Sloan Kettering Cancer Center, and are using our breakthrough LipidSense™ platform to hunt for novel targets and create new drugs that modulate aberrant lipid metabolism in many forms of cancer, metabolic diseases, lysosomal storage diseases, and neurodegenerative disorders.
Leadership
Team
Scientist
Scientific and Chemistry Advisory Board
Robert Schwartz, MD, PhD
Weill Cornell Medicine
Matthew
Vander Heiden, MD, PhD
Massachusetts Institute of Technology (MIT)
Rushika Perera, PhD
University of California,
San Francisco
Tuomas Tammela, MD, PhD
Memorial Sloan Kettering Cancer Center
Xuejun Jiang, PhD
Memorial Sloan Kettering Cancer Center
Francis Tavares, PhD
ChemoGenics BioPharma
Business Advisors
Robin Mansukhani
CEO, Deciduous Therapeutics
Jeff Hatfield, MBA
Chairman of the Board of Directors, Vividion Therapeutics and ROME Therapeutics
Technology
Creating Lipid-Altering Therapeutics
Lipid dysfunction is a hallmark of a broad range of diseases such as cancer, metabolic diseases, lysosomal storage diseases, and neurodegenerative disorders. Despite this, efforts to hunt for lipid-mediated targets and create novel therapies have remained elusive due to lack of technology.
We've changed the game with the invention of an ultrasensitive lipid detection technology. LipidSense is a high-throughput screening platform that monitors lysosomal lipid flux in real time in live cells, in a high-throughput screening format, and in live animals.
We can tell within seconds whether a particular therapy changes lipid flux. We are utilizing this platform to discover drugs that can alter cancer's access to lipids or restore lysosomal lipid function in metabolic diseases and neurodegenerative disorders.
Ultimately, we are exploring therapeutic opportunities to touch the lives of 100 million patients.
Publications
A Carbon Nanotube Optical Reporter Maps Endolysosomal Lipid Flux.
Prakrit V. Jena, Daniel Roxbury, et. al.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707631/
An optical nanoreporter of endolysosomal lipid accumulation reveals enduring effects of diet on hepatic macrophages in vivo.
Thomas V. Galassi, Prakrit V. Jena, et. al.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543545/
Long-term in vivo biocompatibility of single-walled carbon nanotubes
Thomas V. Galassi, et. al., and Daniel Heller
News and Events
Lime Therapeutics Announces Collaboration with
Novo Nordisk BioInnovation Hub
February 14, 2024
Lime Therapeutics Holds Scientific Advisory Board Meeting
October 25, 2023
Lime Therapeutics Presents at BIO Investor Forum
September 25, 2023
Lime Therapeutics Participates in New York Bio Annual Meeting
August 31, 2023
Lime Therapeutics Featured in Biomarker
July 23, 2023
Lime Therapeutics Announces New Scientist Hire - Dr. Mariluz Soula
April 23, 2023
Lime Therapeutics Presents "Lightning Talk" at Advanced Science Research Center Symposium
February 28, 2023
Bristol Myers Squibb Awards Lime Therapeutics with a “Golden Ticket”
Our Supporters
Thank you to those supporting our efforts to develop life-changing therapeutics (partial list):
_edited.png)
_edited.png)
Case Western Reserve University
Alumni Venture Fund
Little Green Bamboo
Invest together. Grow together.
Kent Johnson, MBA
Former CFO, BioLegend
Inaki Berenguer, PhD, MBA
Life Extension Ventures
If interested in pursuing an investment opportunity, please reach out.